黑色素瘤中的BRAF突变:生物学方面,治疗影响和循环生物标志物
Giorgia Castellani1, Mariachiara Buccarelli1, Maria Beatrice Arasi1
1Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Cancers
|August 26, 2023
概括
BRAF突变驱动黑色素瘤的发病并影响治疗反应. 了解耐药机制和循环生物标志物对于改善BRAF突变黑色素瘤患者的治疗结果至关重要.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 分子生物学分子生物学
背景情况:
- 黑色素瘤是一种侵袭性皮肤癌,由黑色素细胞的转化引起.
- 向疗法和免疫疗法改善了黑色素瘤患者的治疗结果.
- BRAF突变,特别是V600E,在黑色素瘤中很常见,激活MAPK通路.
研究的目的:
- 审查BRAF突变状态在黑色素瘤发病过程中的作用.
- 检查BRAF对黑色素瘤分化和炎症的影响.
- 讨论BRAF突变黑色素瘤中针对性治疗的耐药性机制.
- 对黑色素瘤管理的循环生物标志物的概述.
主要方法:
- 在黑色素瘤中对BRAF突变的文献综述.
- 对BRAF/MEK/ERK通路激活的分析.
- 对黑色素瘤分化和炎症的检查.
- 对抗 BRAF 抑制剂的耐药性机制的审查.
- 对循环生物标志物 (ctDNA,CTC,ncRNA) 的调查.
主要成果:
- BRAF突变是黑色素瘤发展的关键驱动因素.
- BRAF 抑制剂提供了有前途的治疗结果.
- 治疗耐药性仍然是一个重大挑战.
- 循环生物标志物显示出监测黑色素瘤的潜力.
结论:
- 在黑色素瘤的发病和治疗中,BRAF突变状态至关重要.
- 了解抵抗机制对于克服治疗失败至关重要.
- 循环生物标志物为BRAF突变黑色素瘤提供了非侵入性监测策略.
相关概念视频
Skin Cancer
4.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.2K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


